Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VES001 in Asymptomatic GRN-FTD Carriers
NCT06705192Phase 1Completed
- Sponsor
- Mads Kjolby
- Start
- Dec 2024
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of VES001 in frontotemporal dementia (FTD), sponsored by Mads Kjolby. Primary endpoints: Change in PGRN levels in CSF at Day 84 and Change in PGRN levels in plasma at Day 84. Started Dec 2024; status: completed.
02
Drugs
VES001
03
Conditions
frontotemporal dementia (FTD)
Beyond the preview
Go deeper on NCT06705192.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06705192.